These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 16897433)

  • 1. Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
    Skedgel C; Rayson D; Dewar R; Younis T
    Breast Cancer Res Treat; 2007 Mar; 101(3):325-33. PubMed ID: 16897433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
    Skedgel C; Rayson D; Dewar R; Younis T
    Breast; 2007 Jun; 16(3):252-61. PubMed ID: 17207623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
    Gil JM; Rubio-Terrés C; Del Castillo A; González P; Canorea F
    Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
    Rocchi A; Verma S
    Support Care Cancer; 2006 Sep; 14(9):917-27. PubMed ID: 16596419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
    Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
    Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer.
    Erman A; Nugent A; Amir E; Coyte PC
    Breast Cancer Res Treat; 2014 Jun; 145(2):267-79. PubMed ID: 24771048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer From a US Payer Perspective.
    Xie J; Hao Y; Zhou ZY; Qi CZ; De G; Glück S
    Clin Breast Cancer; 2015 Oct; 15(5):e263-76. PubMed ID: 26048087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.
    Younis T; Rayson D; Dewar R; Skedgel C
    Ann Oncol; 2007 Feb; 18(2):293-8. PubMed ID: 17095569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.
    Risebrough NA; Verma S; Trudeau M; Mittmann N
    Cancer; 2007 Aug; 110(3):499-508. PubMed ID: 17592825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.
    Thompson D; Taylor DC; Montoya EL; Winer EP; Jones SE; Weinstein MC
    Value Health; 2007; 10(5):367-76. PubMed ID: 17888101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
    Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
    Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
    Karnon J; Delea T; Barghout V
    Eur J Health Econ; 2008 May; 9(2):171-83. PubMed ID: 17602251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
    Dubsky PC; Jakesz R; Mlineritsch B; Pöstlberger S; Samonigg H; Kwasny W; Tausch C; Stöger H; Haider K; Fitzal F; Singer CF; Stierer M; Sevelda P; Luschin-Ebengreuth G; Taucher S; Rudas M; Bartsch R; Steger GG; Greil R; Filipcic L; Gnant M
    J Clin Oncol; 2012 Mar; 30(7):722-8. PubMed ID: 22271481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE; El-Ouagari K; Karnon J; Sofrygin O
    Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.